Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) has shared an announcement.
Genflow Biosciences Plc announced that its total issued share capital as of May 30, 2025, consists of 453,547,942 ordinary shares, all of which carry voting rights. This information is crucial for shareholders to determine their reporting obligations under the Financial Conduct Authority’s rules. The announcement highlights Genflow’s commitment to transparency and may influence investor decisions regarding their stakes in the company.
More about Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Plc is a biotechnology company based in the UK with research and development facilities in Belgium. The company focuses on pioneering gene therapies aimed at decelerating the aging process to promote longer and healthier lives, addressing the challenges posed by a rapidly aging global population. Genflow’s lead compound, GF-1002, targets the SIRT6 gene and is set to undergo clinical trials in 2025 to explore its potential in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease.
Average Trading Volume: 2,603,751
Technical Sentiment Signal: Sell
Learn more about GENF stock on TipRanks’ Stock Analysis page.